Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Maria Dayao"'
Autor:
Richard Austin, Sony Rocha, Kathryn Kwant, Maria Dayao, Wade Aaron, Evan Callihan, Golzar Hemmati, Kevin Wright, Yinghua Xiao, Timothy Yu, Jessica O’Rear, Stephen Yu, Avneel Hundal, Bryan Lemon, Holger Wesche, Katrina Stephenson, Subramanian Thothathri, Rose Banzon, Eric Bragg, Willis Kwong, Hubert Situ, Taggra Jackson, Linh To, S Jack Lin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/312e28f04efa43879714a1ce7e252c2a
Autor:
Richard Austin, Thomas Evans, Jack Lin, Sony Rocha, Kathryn Kwant, Maria Dayao, Tessie Ng, Wade Aaron, Evan Callihan, Maria Gamez-Guerrero, Golzar Hemmati, Kevin Wright, Manasi Barath, Yinghua Xiao, Master Degree, Timothy Yu, Patrick Chew, Jessica O’Rear, Scott Gatto, Michael Cremin, Stephen Yu, Purbasa Patnaik, Avneel Hundal, Bryan Lemon, Holger Wesche
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/2a870365be484e02a43711d26308d88c
Autor:
Kevin Wright, Jack Lin, Richard C. Austin, Maria Dayao, Lemon Bryan D, Master Degree, Michael Cremin, Stephen Yu, Purbasa Patnaik, Jessica O’Rear, Holger Wesche, Golzar Hemmati, Sony Rocha, Maria Gamez-Guerrero, Tessie M. Ng, Yinghua Xiao, Avneel Hundal, Scott Gatto, Kathryn Kwant, Tom Evans, Timothy Yu, Manasi Barath, Patrick Chew, Evan Callihan, Wade Aaron
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Epithelial cell adhesion molecule (EpCAM) is highly expressed in many solid tumors. However, therapeutics targeting EpCAM have had limited clinical utility or failed in clinical development likely due to the expression of EpCAM in normal t
Autor:
Katrina Stephenson, S. Jack Lin, Kevin Wright, Hubert Situ, Richard C. Austin, Lemon Bryan D, Yinghua Xiao, Subramanian Thothathri, Sony Rocha, Holger Wesche, Taggra Jackson, Avneel Hundal, Wade Aaron, Evan Callihan, Linh To, Maria Dayao, Eric Bragg, Willis Kwong, Golzar Hemmati, Timothy Yu, Stephen Yu, Kathryn Kwant, Jessica O’Rear, Rose Banzon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundCD3-targeted T cell engagers are potent anti-tumor therapies, but their development often requires management of cytokine release syndrome (CRS). Subcutaneous dosing is a promising strategy to reduce CRS, but its application is limited by i
Autor:
Timothy Yu, Raphaela Rose Banzon, Sony Rocha, Holger Wesche, Stephen Yu, Subramanian Thothathri, Yinghua Xiao, Jessica O’Rear, Kathryn Kwant, Kevin Wright, Purbasa Patnaik, Manasi Barath, Richard J. Austin, Avneel Hundal, S. Jack Lin, Golzar Hemmati, Lemon Bryan D, Tessie M. Ng, Scott Gatto, Wade Aaron, Evan Callihan, Linh To, Maria Dayao, Eric Bragg
Publikováno v:
Cancer Research. 81:933-933
T cell engagers have compelling clinical activity, but their use is limited by the availability of tumor targets with minimal normal tissue expression. Conditionally active T cell engagers designed to be active only in the tumor and to spare normal t